Teleflex (TFX)
Health Care · medical devices · NYSE
Teleflex provides essential, specialty medical technologies used in critical care and surgical procedures to improve patient outcomes.
What Teleflex does
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. The company focuses on specialty medical devices for critical care, surgical, and cardiac procedures, serving healthcare providers and hospital systems worldwide.
Themes: critical care technology, surgical innovation, vascular access, medical device manufacturing
Fundamentals
- Price$138.83 as of 2026-08-21 close
- Market cap$5.9B as of 2026-08-21
- 1-year return+11.4% 2025-08-21 close $124.61 → 2026-08-21 close $138.83
- P/En/a negative earnings
- Net margin-39.7% as of 2026-08-24
- Gross margin+53.8% as of 2026-08-24
- ROE-31.9% as of 2026-08-24
- Debt / equity0.97 as of 2026-08-24
- Revenue growth (YoY)-14.5% as of 2026-08-24
- Revenue CAGR (3y)-10.6% SEC XBRL
- Beta0.81 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.6%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How TFX compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- indicated dividend yieldbottom 25% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
TFX is not currently in any published Top 10 list. Its scores are below.
Long-term score
38.0 #859 of 987 scored · #51 of 57 in Health Care
Capital return 71st (consecutive years of dividend increases 5 years) and valuation 71st (price to book 1.7); weakest is profitability (2nd, return on equity -31.9%, operating margin -11.7%).
Short-term score
60.8 #177 of 1,704 scored · #42 of 240 in Health Care
Volume and participation 85th: trading volume is about normal versus its 30-day average; setup 64th: no fresh 20-day breakout up or down; weakest is momentum 46th: MACD momentum is negative.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, TFX's dividend exceeded at least one reported measure of what it earned or generated (free-cash-flow payout 4168%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payoutnot assessable earnings were not positive that year
- Free-cash-flow payout4168% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Teleflex looks technically
Teleflex (TFX) is trading 14.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 76 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative). It made a new 20-day high about 14 trading days ago. It is 4.3% below its 52-week high (its highest price of the past year).
Trend
7
| Distance from the 200-day | it is trading 14.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +14.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $132.68 | $132.68 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $121.62 | $121.62 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 76 trading days ago — a "golden cross", a bullish long-term signal | 76 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend) | 11.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30) | 57.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($130.03 to $145.00) — its "stochastic" reading is 59 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 58.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $145.00 | $145.00 |
|---|---|---|
| From the 52-week high | it is 4.3% below its 52-week high (its highest price of the past year) | -4.3% |
| Above the 52-week low | it is 38.5% above its 52-week low (its lowest price of the past year) | +38.5% |
| Below the 52-week high | it is 4.3% below its highest point of the past year | 4.3% |
| Since a 20-day breakout | it made a new 20-day high about 14 trading days ago | 14 sessions |
| Since a 55-day breakout | it made a new 55-day high about 14 trading days ago | 14 sessions |
| All-time high | its highest closing price on record is $449.38 (set on 2021-04-28) | $449.38 |
| Given back of the 52-week move | over the past year its closes ranged ($100.34 to $140.12), and it has given back only a small part of its rise from last year’s low — 3% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $114.26 to $115.54. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.2% |
| From the all-time high | it is 69.1% below its all-time high | -69.1% |
| Nearest price level | it is sitting right on a resistance level at $139.26 — a price it turned at three times since 2025-04-29, most recently on 2026-07-17. Since 2024-08-21 it has 10 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.3% |
| All-time low | its lowest closing price on record is $37.21 (set on 2009-04-01) | $37.21 |
| Above the all-time low | it is 273.1% above its all-time low | +273.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 88% of it) | 12th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $4.53 between its high and its low — about 3.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $4.53 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $130.40 and $140.74 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $130.40 – $135.57 – $140.74 |
| Typical daily range (% of price) | its price moves about 3.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.3% |
| Stretch from the 200-day average | it is trading 3.8 daily ranges above its 200-day average price (14.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.24× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.2% since the prior reading | +1.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.2% |
|---|---|---|
| Gap filled | a 3.2% gap up opened on 2026-08-06 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 11 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 0.5 percentage points (the stock gained 2.8% while the market gained 2.3%) | +0.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 2.2 percentage points (the stock gained 5.3% while the market gained 3.1%) | +2.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 9.2 percentage points (the stock gained 20.3% while the market gained 11.1%) | +9.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 9.1 percentage points (the stock gained 11.4% while the market gained 20.5%) | -9.1% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.4% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.1% of the share price. | +5.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 15% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $121.04 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +14.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $135.74 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +2.3% |
Price levels it has turned at before
TFX last closed at $138.83 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $139.26 | Resistance | 0.3% above the last close | turned there three times · 2025-04-29 to 2026-07-17 |
| $136.11 | Support | 2.0% below the last close | turned there four times · 2025-10-22 to 2026-05-20 |
| $142.79 | Resistance | 2.9% above the last close | turned there three times · 2025-03-10 to 2025-04-02 |
| $133.38 | Support | 3.9% below the last close | turned there twice · 2025-09-11 to 2026-06-05 |
| $130.91 | Support | 5.7% below the last close | turned there five times · 2025-05-12 to 2026-08-06 |
| $172.18 | Resistance | 24.0% above the last close | turned there twice · 2024-12-19 to 2025-01-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · trendless / choppy (low ADX) · Analyst price target recently RAISED · beating the market · Printed a bullish engulfing pair · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.54 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$152.55 range $138.00 – $169.00; median $155.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TFX
- Consensus EPS estimate$1.89 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant fluctuations in operating performance and profitability, as evidenced by recent net losses and declining margins.","Potential for impairment charges and restructuring costs impacting financial stability.","Exposure to foreign currency translation risks."]
What changed in the latest 10-Q
AI-assisted comparison of TFX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-07) adds 'supporting high-acuity emergent procedures' to describe the procedures for which medical devices are used
- Newer filing adds comprehensive 'Recent Strategic Actions' section detailing announced divestitures of Acute Care, Interventional Urology, and OEM businesses to Intersurgical Ltd and Montagu/Kohlberg for $2.0 billion total consideration, with expected completion in Q3 2026 and H2 2026
- Newer filing adds section on transition services agreements and other arrangements between Teleflex and buyers following closings
- Newer filing adds disclosure that Strategic Divestitures were classified as discontinued operations and held for sale beginning December 31, 2025
- Newer filing adds 'Leadership updates' section documenting departure of Liam J. Kelly on January 8, 2026, appointment of Stuart A. Randle as Interim President and CEO, appointment of Stephen K. Klasko as independent Chair, announcement on April 9, 2026 of leadership transitions, and appointment of Jason Weidman as President and CEO effective June 8, 2026
- Newer filing adds $2.5 million severance expense recognized in Q1 2026 related to former CEO's departure
- Newer filing adds 'Litigation settlement' section disclosing April 6, 2026 settlement with medical device company involving patent infringement claims, resulting in $25.0 million monetary consideration to Teleflex
- Newer filing adds disclosure of February 20, 2026 U.S. Supreme Court decision invalidating tariffs imposed under IEEPA and Administration's announcement of new Executive Orders imposing tariffs under alternative statutory authority
- Removed:
- Older filing (2025-11-06) describes devices used 'for common diagnostic and therapeutic procedures in critical care and surgical applications'; newer filing removes these specific procedure descriptors
- Older filing states company 'may identify opportunities to divest businesses and product lines that do not meet our objectives'; newer filing removes this language and replaces with broader restructuring framework
- Older filing describes distributor conversions as involving 'particularly in Asia, the conversions involve our acquisition or termination of a master distributor'; newer filing removes geographic specificity
- Older filing contains 'Recently Announced Strategic Actions' section describing February 27, 2025 separation announcement into two independent companies (one retaining Vascular Access and Interventional Access, second company being 'NewCo' comprising Acute Care, IU, and OEM); newer filing removes this section entirely
- Older filing discusses active pursuit of potential sale of NewCo with no guarantees of completion; newer filing removes this language in favor of definitive divestiture agreements
- Older filing contains extended 'Impairment considerations' section documenting $403.9 million goodwill impairment charge for IU reporting unit in Q3 2025 and Titan SGS asset group impairment analysis; newer filing removes this entire impairment section
- Reworded:
- Older filing: 'we may seek to optimize utilization of our facilities through restructuring initiatives designed to further improve our cost structure'; newer filing: 'we may seek to optimize utilization of our facilities through restructuring initiatives designed to further reduce our cost base'
- Older filing describes acquisition completion as 'On June 30, 2025, the first day of the third fiscal quarter of 2025, we completed the acquisition'; newer filing: 'In the third quarter of 2025, we completed the acquisition'
- Older filing includes detailed discussion of foreign exchange derivative contracts and settlement proceeds of $82.2 million; newer filing removes these details
- Older filing provides details about ancillary agreements with BIOTRONIK relating to transition support and distribution services with varying durations up to 36 months; newer filing simplifies to general reference to transition services agreements
- Notes:
- The newer filing appears truncated at the end of the tariff discussion section, so any additional content beyond that point cannot be assessed
- The older filing's impairment considerations section is also truncated mid-sentence, limiting full comparison of that section
- The strategic direction changed materially from a planned two-company separation to definitive divestiture agreements, representing a significant shift in disclosed strategy rather than incremental changes
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for TFX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 3 matched disclosures for TFX from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding TFX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 8,157,565
- Reported value $975,726,270
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
TFX had 3,027,778 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
TFX had 7.15% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.02 days to cover at the same settlement.
- Reported short interest (shares) 3,027,778
- Short interest (% of shares outstanding) 7.15%
- Prior settlement (shares) 2,783,655
- Reported change 8.77%
- Days to cover (reported) 7.02
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Becton, Dickinson and Company (BDX)
- Edwards Lifesciences (EW)
- Baxter International (BAX)
- Cook Medical
- B. Braun Melsungen AG
- Boston Scientific (BSX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TFX vs…
Frequently asked questions
What does Teleflex (TFX) do?
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. The company focuses on specialty medical devices for critical care, surgical, and cardiac procedures, serving healthcare providers and hospital systems worldwide.
What sector is Teleflex (TFX) in?
Teleflex (TFX) is classified in the Health Care sector. Its industry is medical devices. It trades on NYSE.
Does TFX pay a dividend?
Yes — Teleflex (TFX) pays a dividend, with an indicated yield of about 0.62% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Teleflex's (TFX) competitors?
Notable peers of Teleflex (TFX) include Becton, Dickinson and Company, Edwards Lifesciences, Baxter International, Cook Medical and B. Braun Melsungen AG. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in TFX?
Yes — we hold 3 matched STOCK Act disclosures for TFX from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Teleflex (TFX) overbought or oversold right now?
Teleflex (TFX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 57, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TFX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.